PHIBRO ANIMAL HEALTH CORP (PAHC) Form 10-Q — Nov 4, 2026
Phibro Animal Health reported Q1 FY2027 net sales of $386.8 million, up 6% year over year, with net income up 11% to $29.5 million and diluted EPS of $0.72 versus $0.65. Mineral Nutrition (+17%) and Performance Products (+16%) led growth, while Animal Health rose 3%. Adjusted EBITDA increased 4% to $64.3 million and adjusted diluted EPS rose 8% to $0.79. The company recovered $12.3 million of IEEPA tariff refunds following the Supreme Court ruling striking down the tariffs, and maintained $308.9 million of revolver availability.
Key figures
- Eps
- 0.72
- Revenue
- 386774000
- Net Income
- 29520000
- Total Debt
- 615619000
- Revenue Yoy
- 6%
- Total Assets
- 1514722000
- Cash Position
- 75548000
- Gross margin
- 33.2%
- Adjusted ebitda
- 64284000
- Dividend per share
- $0.12 declared November 3, 2026, payable December 16, 2026
- Israeli assets pct
- 17% of consolidated assets
- Adjusted diluted eps
- 0.79
- Mecadox annual sales
- approximately $22 million
- Revolver availability
- 308917000
- Diluted eps prior year
- 0.65
- Shares outstanding class a
- 21105569
- Shares outstanding class b
- 19496034
- Ieepa tariff refunds confirmed
- 13400000
- Ieepa tariff refunds recovered
- 12300000
- Brazil virginiamycin sales decline
- decreased $5.2 million for the three months ended September 30, 2026
- Chicago heights closure cost estimate
- 5000000
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.